Nova Leap HealthNVLPF 50 Debt-to-EBITDA is 1.04 as of Mar. 2026, which is 22% below its 10-year median of 1.33. GuruFocus rates NVLPF with a GF Score™ of 50/100 and a GF Value™ of $0.22 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 477 Healthcare Providers & Services companies, Nova Leap Health ranks better than 57.65% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nova Leap Health's Debt-to-EBITDA or its related term are showing as below:
NVLPF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -16.21 Med: 1.33 Max: 44.51
Current: 1.83
During the past 10 years, the highest Debt-to-EBITDA Ratio of Nova Leap Health was 44.51. The lowest was -16.21. And the median was 1.33.
NVLPF's Debt-to-EBITDA is ranked better than 57.65% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs NVLPF: 1.83
Nova Leap Health (OTCPK:NVLPF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nova Leap Health Debt-to-EBITDA Related Terms
Nova Leap Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Nova Leap Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Nova Leap Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Leap Health Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nova Leap Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nova Leap Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Nova Leap Health (NVLPF) has a Debt-to-EBITDA of 1.04 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nova Leap Health. This is 22% below median its historical median of 1.33. According to the industry distribution chart, Nova Leap Health ranks #202 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 42.3%.
Is Nova Leap Health's Debt-to-EBITDA too high?
Nova Leap Health's current Debt-to-EBITDA of 1.04 is 22% below median its 10-year median of 1.33. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. Nova Leap Health's value of 1.04 is 53.2% below this industry median. Based on the distribution chart, Nova Leap Health ranks #202 out of 477 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Nova Leap Health has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nova Leap Health's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Nova Leap Health ranks #202 out of 477 companies for Debt-to-EBITDA. This puts Nova Leap Health in the upper half of its industry. The industry median Debt-to-EBITDA is 2.22. Nova Leap Health's value of 1.04 is 53.2% below this benchmark. While the company's 10-year median is 1.33 vs. the industry median of 2.22, Nova Leap Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nova Leap Health's current Debt-to-EBITDA of 1.04 is 53.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nova Leap Health. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Leap Health's current Debt-to-EBITDA is 1.04, which is 22% below median its own 10-year median of 1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Leap Health stock overvalued right now?
Based on GuruFocus' analysis, Nova Leap Health (NVLPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.22, compared to a current price of $0.26 — trading 18.2% above its estimated fair value. The current Debt-to-EBITDA is 1.04, which is 22% below median its 10-year median of 1.33 and 53.2% below the Healthcare Providers & Services industry median of 2.22. Nova Leap Health's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nova Leap Health (NVLPF), the current Debt-to-EBITDA is 1.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Leap Health (NVLPF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Leap Health stock appears to be overvalued.
The current stock price of $0.26 is trading 18.2% above its estimated GF Value™ of $0.22.
GuruFocus considers Nova Leap Health to be Modestly Overvalued.
Key valuation signals for NVLPF:
Debt-to-EBITDA: 1.04 (22% below median its 10-year median of 1.33)
GF Value™: $0.22 vs. price of $0.26 (18.2% above fair value)
Industry Position: 53.2% below the Healthcare Providers & Services median (#202 of 477)
No single metric tells the full story. See the NVLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Leap Health Corp operates in the healthcare industry. The company is a provider of home and home health care services to clients..The principal business activities of the company and its subsidiaries are to provide skilled and non-medical home care to clients. Its service offerings include meal preparation, housekeeping, transportation, personal care, and medication reminders. Its segments comprise Canadian and U.S. operations. The company derives a majority of its revenue from the United States.
50GF Score
Get the complete analysis for NVLPF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVLPF has been successfully added to your 
